Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters - patient centered endpoints in trials of mainten
| Image |  |
|---|---|
| Description | scientific article published on 18 December 2017 |
| Author/s |
author: Jae-Weon Kim Philip R. Debruyne |
| Publication date | March 1, 2018 |
| Language | |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |